Capital Fund Management (CFM)
CLDX icon

Capital Fund Management (CFM)’s Celldex Therapeutics CLDX Stock Holding History

Capital Fund Management (CFM)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
+28,417
New +$918K ﹤0.01% 1684
2025
Q2 		– Sell
-15,501
Closed -$281K – 2361
2025
Q1 		$281K Sell
15,501
-19,818
-56% -$443K ﹤0.01% 1916
2024
Q4 		$893K Sell
35,319
-548
-2% -$14.9K ﹤0.01% 1784
2024
Q3 		$1.22M Sell
35,867
-8,578
-19% -$327K ﹤0.01% 1628
2024
Q2 		$1.64M Buy
+44,445
New +$1.68M ﹤0.01% 1455
2015
Q3 		– Sell
-647
Closed -$245K – 1442
2015
Q2 		$245K Buy
+647
New +$257K ﹤0.01% 1345
2015
Q1 		– Sell
-1,501
Closed -$537K – 1469
2014
Q4 		$411K Buy
+1,501
New +$373K ﹤0.01% 1215
2014
Q2 		– Sell
-20,441
Closed -$5.42M – 1698
2014
Q1 		$5.42M Sell
20,441
-16,062
-44% -$6.15M 0.07% 337
2013
Q4 		$13.3M Buy
36,503
+32,230
+754% +$12.4M 0.16% 136
2013
Q3 		$2.27M Buy
+4,273
New +$1.47M 0.03% 600

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Fund Management (CFM)'s CLDX Position: Q2 2026 in Review

Capital Fund Management (CFM) opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 28,417 shares worth $1.06M. The stake represents ﹤0.01% of the portfolio and ranks #1684 among its holdings. This is a return to the name: Capital Fund Management (CFM) previously reported a position in CLDX as recently as Q1 2025.

Capital Fund Management (CFM) first reported a position in CLDX in Q3 2013 and has held it in 10 quarters since. The position peaked at $13.3M in Q4 2013. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Capital Fund Management (CFM) held 28,417 shares of Celldex Therapeutics worth $1.06M as of Q2 2026.
  • Celldex Therapeutics was a new Capital Fund Management (CFM) position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1684 holding.
  • Capital Fund Management (CFM) first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 10 quarters since.
  • Capital Fund Management (CFM)'s Celldex Therapeutics position peaked at $13.3M in Q4 2013.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.